Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Pharming Group NV

PHAR ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Pharmaceuticals ·

USA Small Cap Analyst: STRONG BUY

Last Close

$11.72

▼ -5.10%

Market Cap $810.80M · Vol 5.31K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$810.80M

Small Cap

Div Yield

N/A

EPS Growth

+941.75%

YoY

RSI (14)

42.96

Momentum

Beta

0.10

vs Market

52W High

$21.30

44.98% below

52W Low

$9.63

21.70% above

Volume

5.31K

Avg 5.75K

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

100.00%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Pharming Group NV (PHAR) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does PHAR pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+8.72%

-12.64%

-6.76%

-23.99%

YTD

-33.67%

+2.90%

-4.64%

+9.84%

Financials & Valuation

TTM · Annual

Total Revenue	N/A
Net Income	N/A
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	N/A · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	N/A
P/FCF	N/A
EPS Growth	+941.75%
Outstanding Shares	707.78M

Technical Indicators

50-Day SMA	$12.65
200-Day SMA	$15.32
RSI (14)	42.96
Beta	0.10
52-Week High	$21.30
52-Week Low	$9.63

Volume Today	5.31K
Avg Daily Volume (30D)	5.75K
Relative Volume	0.92x
Volatility (10D)	61.78
Volatility (30D)	60.13
Free Float	100.00%

Analyst Consensus

STRONG BUY

Current Price $11.72

Mean Target $2.49

52W Low$9.63 52W High$21.30

Current

Target

$9.63 $21.30

Current Analyst target

-78.74% downside risk · 5 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00YN70W58

ISINUS71716E1055

CountryNetherlands

Sub-IndustryPharmaceuticals (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeADR American Depositary Receipt

Similar Halal Stocks

LLY Eli Lilly and Co -2.39% JNJ Johnson & Johnson -0.66% ABBV Abbvie Inc -0.54% NVS Novartis AG -0.55% NOVN.S Novartis AG -1.05%

Company Profile

Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.